Search

Purpose Around 2000 heart transplants are performed in Europe annually. Primary Graft Dysfunction(PGD) rates in Europe are among the highest in the world. The increasing use of marginal donor organs has been suggested as a potential cause. Novel techniques using ex-vivo normothermic perfusion have garnered increasing interest but incur a significant cost. We present a series of patients who underwent heart transplantation at our unit using a novel implantation technique to reduce PGD that is cost-effective and reproducible Methods The donor heart is removed from cold storage and placed in an ice slush basin on arrival to our unit. An aortic cross clamp is applied distal to the donor ascending aorta. An antegrade infusion of 600mls of cold blood cardioplegia is followed by cold oxygenated blood (4-6°C) to achieve a mean aortic root pressure of 60-70 mmHg. This continuous antegrade perfusion is maintained throughout the left atrium and aortic anastomosis with a left ventricular vent in situ. A warm cardioplegia hotshot is infused into the aortic root prior to removal of the recipient aortic cross-clamp. The remaining anastomoses are carried out in the usual fashion sequentially. We compared our experience with this method with the national UK cohort (2015-2016) of patients (Control Group). We performed multivariable logistic regression comparing the two cohorts with PGD as the primary outcome measure. Confounders adjusted for include donor age, recipient age and donor-recipient gender mismatch. Results 139 (71.6 %) patients were male. 46(18.6%) of the patients had ischemic cardiomyopathy. The odds ratio of PGD in the control group was 2.99 (95% CI 1.02- 8.75) when compared to the Extended Cooling. Conclusion This novel approach is associated with significant reductions in PGD rates post-transplantation likely due to the shorter warm ischemic time. Larger studies are needed to show differences after further adjustment for known confounders of PGD. We believe this novel technique is safe, cost-effective and reproducible. [ABSTRACT FROM AUTHOR]

Objectives: Around 2000 heart transplants are performed in Europe annually. The rates of primary graft dysfunction in Europe are among the highest in the world. With increasing demand for organs and the limited supply of donors, novel techniques such as ex vivo normothermic perfusion have garnered incre-asing interest. We present a series of patients who underwent heart transplant at our unit in which we used a novel implantation technique to reduce primary graft dysfunction., Materials and Methods: We compared our experience with the novel method detailed in our article (Glasgow experience group) with a contemporary UK cohort (2015-2016) of patients (control group). We performed multivariable logistic regression to compare the Glasgow experience with the control group with primary graft dysfunction as the outcome measure. We adjusted for donor age, recipient diabetes mellitus, urgent listing status, bypass time, and total ischemic time., Results: Among 194 patients in both cohorts, 140 patients (72.1%) were men and 36 (18.6%) had ischemic cardiomyopathy. The odds ratio of primary graft dysfunction in the control group was 2.99 (95% CI, 1.02- 8.75) compared with the Glasgow experience group., Conclusions: Our novel approach was associated with significant reductions in primary graft dysfunction, with a trend toward improved 1-year survival. Larger studies are needed to show differences after further adjustment for known confounders of primary graft dysfunction. We believe this novel technique is safe, cost-effective, and reproducible.

Aims: To critically review the available transcatheter aortic valve implantation techniques and their results, as well as propose recommendations for their use and development., Methods and Results: A committee of experts including European Association of Cardio-Thoracic Surgery and European Society of Cardiology representatives met to reach a consensus based on the analysis of the available data obtained with transcatheter aortic valve implantation and their own experience. The evidence suggests that this technique is feasible and provides haemodynamic and clinical improvement for up to 2 years in patients with severe symptomatic aortic stenosis at high risk or with contraindications for surgery. Questions remain mainly concerning safety and long-term durability, which have to be assessed. Surgeons and cardiologists working as a team should select candidates, perform the procedure, and assess the results. Today, the use of this technique should be restricted to high-risk patients or those with contraindications for surgery. However, this may be extended to lower risk patients if the initial promise holds to be true after careful evaluation., Conclusion: Transcatheter aortic valve implantation is a promising technique, which may offer an alternative to conventional surgery for high-risk patients with aortic stenosis. Today, careful evaluation is needed to avoid the risk of uncontrolled diffusion.